Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

We evaluated the pharmacokinetics, pharmacodynamics, and safety of evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), in an open‐label, parallel‐design study in participants with normal renal function (n = 6), severe renal impairment (RI; n =...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Pharmacol Drug Dev
Glavni autori: Lee, Edward, Gibbs, John P., Emery, Maurice G., Block, Geoffrey, Wasserman, Scott M., Hamilton, Lisa, Kasichayanula, Sreeneeranj, Hanafin, Patrick, Somaratne, Ransi, Egbuna, Ogo
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590207/
https://ncbi.nlm.nih.gov/pubmed/30676701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.650
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items